MTOR and Parkinson disease: There are many LRRK2 mutations reported in PD patients, of which the G2019S mutation in the kinase domain is the most prevalent, and has been shown to regulate the mTOR pathway via p-4E-BP1 and AKT, resulting in an increase in bulk translation, which leads to neurotoxicity and neurological disorders [166,167].